Co-Authors
This is a "connection" page, showing publications co-authored by JASON ROBERT WESTIN and ROBERT ORLOWSKI.
Connection Strength
0.186
-
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630.
Score: 0.037
-
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
Score: 0.035
-
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 05; 30(5):1005-17.
Score: 0.034
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
Score: 0.031
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.029
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb; 22(2):414-23.
Score: 0.019